# US 2025/0154689 A1 · Library of Antigen-Binding Molecules Including Modified Antibody Variable Region

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154689 A1
- Document ID: US20250154689A1
- Status: Published application
- Kind: A1
- Application number: 19/024,740
- Filed: 2025-01-16
- Published: 2025-05-15
- Earliest claimed: 2014-11-11
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Applicants: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Tomoyuki Igawa; Shojiro Kadono; Naoka Hironiwa; Mika Sakurai
- Web page: https://patentgrep.com/patent/US20250154689A1

## CPC

- C40B 40/10: Libraries containing peptides or polypeptides, or derivatives thereof
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2848: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/42: against immunoglobulins
- C12N 15/09: Recombinant DNA-technology
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/55: Fab or Fab'
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present inventors have successfully prepared a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, the antigen-binding molecules each comprising an antibody variable region that has binding activity against a first antigen and a second antigen different from the first antigen, but does not bind to the first antigen and the second antigen at the same time. Use of the library of the present invention allows the obtainment of a variable region having enhanced ability to bind to the first antigen and the production of a bispecific antibody against the first antigen and a cancer antigen. Moreover, the present inventors have also successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against three different antigens, but does not bind to these antigens at the same time.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A library comprising a plurality of antigen-binding polypeptide molecules that differ from each other in amino acid sequence, wherein:
each antigen-binding polypeptide molecule of the plurality comprises an antibody variable region that can bind to a first antigen and a second antigen, but not at the same time;
one of the antigens is CD3;
the other antigen is not CD3;
the antibody variable regions of the plurality of antigen-binding polypeptide molecules differ from each other in amino acid sequence;
each antibody variable region comprises a heavy chain variable region (VH) and a light chain variable region (VL); and
the VH comprises the amino acid sequence of SEQ ID NO: 96 or an altered SEQ ID NO: 96, the alterations in SEQ ID NO: 96 being at one or more positions selected from Kabat numbering positions 31 to 35, 50 to 65, 71 to 74, and 95 to 102 in an antibody H chain variable domain.

### Claim 28 (depends on 27)

The library of claim 27, wherein the differences in sequence between at least some of the antibody variable regions include a peptide present in a loop being within or comprising part or all of a VH CDR1 region, a VH CDR2 region, a VH CDR3 region, or a VH FR3 region, wherein the peptide binds to one of the antigens.

### Claim 29 (depends on 28)

The library of claim 28, wherein the peptide is present within the VH CDR3 region of at least some of the antibody variable regions.

### Claim 30 (depends on 27)

The library of claim 27, wherein the antigen that is not CD3 is a molecule expressed on the surface of a naturally-occurring immunocyte.

### Claim 31 (depends on 27)

The library of claim 27, wherein the antigen that is not CD3 is selected from the group consisting of: an FcγR, a toll like receptor (TLR), a lectin, an immune checkpoint molecule, a tumor necrosis family receptor (TNFR) superfamily molecule, and a natural killer (NK) cell receptor molecule.

### Claim 32 (depends on 27)

The library of claim 27, wherein the antigen that is not CD3 is independently selected from an IgA, a tumor necrosis factor (TNF) superfamily molecule, and a surface antigen of a T cell or of another type of immunocyte.

### Claim 33 (depends on 27)

The library of claim 27, wherein the antigen-binding polypeptide molecules are fusion polypeptides.

### Claim 34 (depends on 33)

The library of claim 33, wherein each fusion polypeptide comprises a portion of a viral coat protein.

### Claim 35 (depends on 27)

The library of claim 27, wherein each antigen-binding polypeptide molecule further comprises a second antibody variable region that binds to a third antigen that is different from the first antigen and the second antigen.

### Claim 36 (depends on 35)

The library of claim 35, wherein each of the second antigen and the third antigen is a surface antigen of a T cell or of another type of immunocyte.

### Claim 37 (depends on 35)

The library of claim 35, wherein each of the second antigen and the third antigen is independently selected from a FcγR, a toll-like receptor (TLR), a lectin, an immune checkpoint molecule, a tumor necrosis factor receptor (TNFR) superfamily molecule, and a natural killer (NK) cell receptor molecule.

### Claim 38 (depends on 35)

The library of claim 35, wherein each of the second antigen and the third antigen is independently selected from an IgA, a tumor necrosis factor (TNF) superfamily molecule, and a surface antigen of a T cell or of another type of immunocyte.

### Claim 39 (depends on 35)

The library of claim 35, wherein the third antigen is a cancer antigen.

### Claim 40 (depends on 27)

The library of claim 27, wherein each antigen-binding polypeptide molecule further comprises an antibody Fc region.

### Claim 41 (depends on 40)

The library of claim 40, wherein the antibody Fc region has a lower binding affinity for a human FcγR as compared to the binding affinity of a naturally occurring human IgG1 Fc region for the human FcγR, wherein the human FcγR is FcγRI, FcγRIIa, or FcγRIII.

### Claim 42 (depends on 27)

The library of claim 27, wherein the binding site for one of the first antigen or the second antigen comprises I to 25 contiguous amino acid residues in one of a VH CDR1 region, a VH CDR2 region, or a VH CDR3 region.

### Claim 43 (depends on 42)

The library of claim 42, wherein the binding site comprises I to 25 contiguous amino acid residues is located in the VH CDR3 region.

### Claim 44 (depends on 27)

The library of claim 27, wherein alterations in SEQ ID NO: 96 are at one or more positions selected from Kabat numbering positions 31, 52b, 52c, 53, 54, 56, 57, 61, 98, 99, 100, 100a, 100b, 100c, 100d, 100e, 100f, and 100g.

### Claim 45 (depends on 27)

The library of claim 27, wherein the alterations in SEQ ID NO: 96 comprise one or more substitutions or insertions or both.

### Claim 46 (depends on 27)

The library of claim 27, wherein the alterations in SEQ ID NO: 96 create binding sites for the antigen that is not CD3 or a third antigen.
